Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Dual-Action drug aims to tackle fatty liver where semaglutide falls short

NCT ID NCT07713992

Not yet recruiting Disease control Sponsor: Tianjin Medical University Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests whether switching to a new drug called mazdutide can reduce liver fat more effectively than staying on semaglutide in people with type 2 diabetes and moderate-to-severe fatty liver. Participants who have been on semaglutide for at least 16 weeks are randomly assigned to either switch to mazdutide or continue semaglutide. The main goal is to measure changes in liver fat using MRI and ultrasound.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a dual GLP-1/glucagon receptor agonist called mazdutide
What this could lead to
If successful, this could offer a new treatment option for people with type 2 diabetes and fatty liver who do not get enough benefit from semaglutide alone.
What could go wrong
This is a relatively small, early-stage trial. The results may not apply to all patients, and mazdutide may cause side effects like nausea or gastrointestinal issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) WITH HISTORY OF DIABETES MELITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) WITH HISTORY OF DIABETES MELITUS TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.